Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00274924 |
|
Recruitment Status :
Completed
First Posted : January 11, 2006
Results First Posted : February 24, 2014
Last Update Posted : November 17, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with stage II, stage III, or stage IV diffuse large B-cell non-Hodgkin's lymphoma.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Lymphoma | Biological: filgrastim Biological: rituximab Drug: carboplatin Drug: cyclophosphamide Drug: doxorubicin hydrochloride Drug: etoposide Drug: ifosfamide Drug: prednisone Drug: vincristine | Phase 2 |
OBJECTIVES:
Primary
- Determine the 2-year progression-free survival (PFS) rate after treatment with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in patients with bulky stage II or stage III or IV diffuse large B-cell non-Hodgkin's lymphoma who remain positron emission tomography (PET)-positive after 3 courses of rituximab, cyclophosphamide, vincristine, doxorubicin hydrochloride, and prednisone.
Secondary
- Determine the proportion of mid-treatment PET-positive patients who become PET-negative after 4 courses of R-ICE.
- Determine the PFS of mid-treatment PET-negative patients treated with these regimens.
- Determine the overall survival of patients treated with these regimens.
- Determine the toxicity of these regimens in these patients.
OUTLINE:
-
Rituximab and Combination Chemotherapy (R-CHOP: R= Rituximab, C= Cyclophosphamide, H= Doxorubicin Hydrochloride (Hydroxydaunomycin), O= Vincristine Sulfate (Oncovin), P= Prednisone): Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1, and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients undergo fludeoxyglucose F18 positron emission tomography (PET) scanning and conventional restaging during course 3. Based on the PET results, patients are assigned to 1 of 2 treatment groups.
- Group I (PET negative): Patients receive 2 more courses of R-CHOP as above in the absence of disease progression or unacceptable toxicity.
- Group II (PET positive): Patients receive Rituximab 375 mg/m2 IV Day 1, Ifosfamide 5000 mg/m2 IV over 24 hours Day 2, Carboplatin AUC 5 (max: 800 mg) IV Day 2, Etoposide 100 mg/m2 IV Days 1, 2, 3 (R-ICE), Mesna 5000 mg/m2 IV over 24 hours Day 2, and Filgrastim 5 mcg/kg/day subcutaneous (SC) Day 4 until absolute neutrophil count (ANC) recovery every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically for 10 years from the date of study entry.
ACCRUAL: A total of 100 patients were accrued for this study.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 100 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Response-Adapted Therapy for Aggressive Non-Hodgkin's Lymphomas Based on Early [18F] FDG-PET Scanning |
| Actual Study Start Date : | April 2006 |
| Actual Primary Completion Date : | June 2013 |
| Actual Study Completion Date : | March 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Group I (PET negative)
Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1, and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
|
Biological: rituximab
Given IV
Other Name: IDEC-C2B8, Chimeric anti-CD20 monoclonal antibody, Rituxan. Drug: cyclophosphamide Given IV
Other Name: Cytoxan, Neosar, CTX, CPM. Drug: doxorubicin hydrochloride Given IV
Other Names:
Drug: prednisone Taken orally
Other Name: Deltasone, Orasone, Medicorten, Panasol-S, Liquid-Pred, others. Drug: vincristine Given IV
Other Name: Oncovin, Vincasar PFS vincristine sulfate, VCR, leucocristine, LCR. |
|
Experimental: Group II (PET positive)
Patients receive R-ICE comprising rituximab IV on day 1, ifosfamide IV continuously over 24 hours and carboplatin IV over 30 minutes on day 2, and etoposide IV over 2 hours on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously once daily starting on day 4 and continuing until blood counts recover. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
|
Biological: filgrastim
Given subcutaneously or intravenous bolus.
Other Names:
Biological: rituximab Given IV
Other Name: IDEC-C2B8, Chimeric anti-CD20 monoclonal antibody, Rituxan. Drug: carboplatin Given IV
Other Name: CBDCA, Paraplatin, JM-8, NSC #241240. Drug: cyclophosphamide Given IV
Other Name: Cytoxan, Neosar, CTX, CPM. Drug: etoposide Given IV
Other Name: VP-16, VePesid, epipodophyllotoxin Drug: ifosfamide Given IV
Other Name: Isophosphamide, Ifex , Mitoxan , Holoxan , Naxamide ' NSC # 109724. |
- 2-year Progression-Free Survival (PFS) [ Time Frame: Assessed every 4 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, then every 12 months if patient is 5-10 years from study entry. ]2-year progression-free survival is defined as the probability of patients who remain alive and progression free at 2 years from study entry. The method of Kaplan and Meier (1958) was used to estimate PFS.
- 5-year Overall Survival [ Time Frame: Every 4 months if patient is < 2 years from study entry, every 6 months if patient is 2-5 years from study entry, then every 12 months if patient is 5-10 years from study entry. ]5-year overall survival is defined as the probability of patients who remain alive at 5 years from study entry. The method of Kaplan and Meier (1958) was used to estimate overall survival.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
-
Diffuse large B-cell non-Hodgkin's lymphoma
- Bulky stage II (bulk defined as any lesion ≥ 10 cm) or stage III or IV disease
-
The following lymphoma types are excluded:
- Primary central nervous system lymphoma
- Transformed low-grade lymphoma (prior history of low-grade lymphoma or clear presence of low-grade lymphoma on histologic sections)
- Primary mediastinal B-cell lymphoma or testicular lymphoma (consolidative radiotherapy is usually indicated)
- Immunodeficiency-related lymphoma (i.e., after organ or bone marrow transplant)
-
Measurable disease
- Patient must have at least one objective measurable disease site (i.e., measurable in at least 2 perpendicular parameters)
- Measurable disease in the liver is required if the liver is the only site of lymphoma involvement
- Abnormal positron emission tomography scans will not constitute evaluable disease, unless verified by CT scan or other appropriate imaging
- Eastern Cooperative Oncology Group (ECOG) performance status 0-3
- For patients > 50 years of age, a normal ejection fraction by ECHO or Multigated Acquisition Scan (MUGA) is required within 6 weeks prior to registration
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count > 100,000/mm^3
- Creatinine < 2.0 mg/dL
- Bilirubin < 2 mg/dL (may be up to 3.0 mg/dL if due to liver involvement by lymphoma)
EXCLUSION CRITERIA:
- Prior chemotherapy or radiation therapy for lymphoma
- Prior anthracyclines or platinum compounds used as systemic chemotherapy
- Prior radiation therapy to the mediastinum or to ≥ 25% of the bone marrow
- Concurrent pentostatin or trastuzumab (Herceptin®)
- Pregnant or nursing
- Prior malignancy within the past 5 years unless it was in situ OR was treated with curative intent AND the patient has remained relapse-free
- HIV positive
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00274924
Show 104 study locations
| Study Chair: | Lode J. Swinnen, MD | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Responsible Party: | Eastern Cooperative Oncology Group |
| ClinicalTrials.gov Identifier: | NCT00274924 |
| Other Study ID Numbers: |
CDR0000455012 U10CA021115 ( U.S. NIH Grant/Contract ) E3404 ( Other Identifier: Eastern Cooperative Oncology Group (ECOG) ) |
| First Posted: | January 11, 2006 Key Record Dates |
| Results First Posted: | February 24, 2014 |
| Last Update Posted: | November 17, 2020 |
| Last Verified: | October 2020 |
|
contiguous stage II adult diffuse large cell lymphoma noncontiguous stage II adult diffuse large cell lymphoma stage III adult diffuse large cell lymphoma stage IV adult diffuse large cell lymphoma |
|
Lymphoma Lymphoma, Non-Hodgkin Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Prednisone Cyclophosphamide Ifosfamide Rituximab Carboplatin Doxorubicin Liposomal doxorubicin |
Etoposide Vincristine Podophyllotoxin Lenograstim Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Antineoplastic Agents, Immunological Antibiotics, Antineoplastic |